Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins

Highlights • Comprehensive pre-clinical immunogenicity evaluation of HPV L1 major capsid protein. • Majority neutralizing antibody response was genotype-specific. • Reciprocal cross-neutralization between some Alpha-7 and Alpha-9 genotypes. • Tetravalent formulation (HPV16/18/39/58) induced broadly...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2014-11, Vol.32 (48), p.6548-6555
Main Authors: Bissett, Sara L, Mattiuzzo, Giada, Draper, Eve, Godi, Anna, Wilkinson, Dianna E, Minor, Philip, Page, Mark, Beddows, Simon
Format: Article
Language:English
Subjects:
Allergy and Immunology
Alphapapillomavirus - genetics
Alphapapillomavirus - immunology
Animals
Antibodies, Neutralizing - blood
Antibodies, Viral - blood
Antibody
Antigenicity
Applied microbiology
Biological and medical sciences
Capsid Proteins - immunology
Cloning
Cross Protection
Diversity
Female
Fundamental and applied biological sciences. Psychology
Genotype
Genotypes
HEK293 Cells
Human papillomavirus
Human papillomavirus 16
Human papillomavirus 18
Humans
Immunization
Immunogenicity
Major capsid protein
Mice, Inbred BALB C
Microbiology
Miscellaneous
Neutralization
Neutralization Tests
Oncogene Proteins, Viral - immunology
Papillomavirus Vaccines - immunology
Proteins
Rabbits
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Comprehensive pre-clinical immunogenicity evaluation of HPV L1 major capsid protein. • Majority neutralizing antibody response was genotype-specific. • Reciprocal cross-neutralization between some Alpha-7 and Alpha-9 genotypes. • Tetravalent formulation (HPV16/18/39/58) induced broadly neutralizing antibodies. • These data improve our understanding of the antigenic diversity of the L1 protein.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2014.07.116